ReportWire

Tag: blood-pressure medication

  • There may soon be a new approach to treat hard-to-control high blood pressure

    [ad_1]

    Doctors may soon have a new way to treat high blood pressure, even among people for whom medicines haven’t worked well in the past.Baxdrostat, an experimental medicine made by AstraZeneca, showed promise in treating people with uncontrolled or resistant high blood pressure in a recent trial. If the medicine gets approved by regulatory authorities, it will be one of the first new approaches to treating high blood pressure in decades, researchers say.Scientists presented the trial results Saturday at the European Society of Cardiology Congress 2025 in Madrid and simultaneously published them in the New England Journal of Medicine.For the study, researchers enrolled 800 adults who still had high blood pressure after taking two or more medications for at least four weeks. To qualify for the study, patients’ systolic blood pressure had to be between 140 and 170.Blood pressure is measured in millimeters of mercury, which is abbreviated as mm Hg. The measurement has an upper number, or systolic reading, and a lower number, a diastolic reading. Systolic pressure measures the force of blood as it pumps out of the heart into the arteries; diastolic is the pressure created as the heart rests between beats.Normal blood pressure is less than 120/80 mm Hg, and elevated blood pressure is considered to be from 120 to 129/80 mm Hg. At 130/80 mmHg or higher, according to new U.S. guidelines, a person’s medical provider will want them to take a blood pressure medication if lifestyle changes — including eating healthier, reducing salt in the diet and exercising more — don’t work first.The researchers on the new trial placed the participants into three groups. One received 1 milligram of baxdrostat, another got 2 mg, and another got a placebo, which does nothing. Participants took their dose in addition to medicines they were already taking.At 12 weeks, about 4 in 10 patients taking baxdrostat reached healthy blood pressure levels, compared with less than 2 in 10 who got a placebo.Specifically, participants who got 1 or 2 mg of baxdrostat daily saw their systolic blood pressure – the upper number in the reading – fall around 9 to 10 mm Hg more than those taking a placebo. This reduction, studies show, is large enough to cut cardiovascular risk.When blood pressure is high, the force of the blood pushes against the walls of their blood vessels, making the heart less efficient: Both the vessels and the heart must work harder, and it’s more difficult to get blood to essential organs and cells. Without treatment, high blood pressure will eventually damage the arteries, raising the risk of conditions like a heart attack, stroke, coronary disease, vascular dementia and cognitive problems.Heart disease is the No. 1 killer in the world. Lowering blood pressure is the most modifiable way to avoid such a death.Nearly half of all adults in the U.S. have higher than normal blood pressure, and 1 in 10 people have what doctors call resistant hypertension: Despite being on three or more medications, they are not meeting the goal for blood pressure control.When a patient has high blood pressure, doctors may need to try a variety of medications to see what works best.Adding baxdrostat to the list of options could be a big help for patients, according to Dr. Stacey E. Rosen, volunteer president of the American Heart Association, who was not involved with the new research.“What’s interesting about this medication is that they can really be a wonderful partner, so to speak, with some of the more classically recommended anti-hypertensive medications,” said Rosen, who is also a senior vice president of women’s health and executive director of the Katz Institute for Women’s Health of Northwell Health in New York City.Medication options now on the market control blood pressure in a variety of ways. Some, such as vasodilators, relax and widen arteries and veins to allow blood to get through easier and increase flow. Diuretics primarily work by removing excess fluid and salt from the body by increasing urine production. Centrally acting alpha agonists help prevent the nervous system from responding to stress. ACE inhibitors keep the body from producing angiotensin II, a hormone that makes blood vessels constrict. ARBs, or angiotensin II receptor blockers, help reduce the production of aldosterone, a hormone that promotes salt and water retention. Calcium channel blockers can keep calcium away from the cells of the heart and arteries so they don’t have to work as hard.Each can have different side effects, including dizziness, rapid or slower heart rate, exhaustion, upset stomach and swelling in the legs.Baxdrostat’s side effects, the study showed, were mild overall. The most common problem was abnormalities in potassium and sodium levels, but this was rare.Baxdrostat takes a new approach to managing high blood pressure. It focuses on blocking aldosterone, a hormone created by the adrenal glands that helps kidneys regulate salt and maintain the body’s water balance. Some people produce too much aldosterone, leading their body to retain too much water and salt, pushing up blood pressure.“We’ve also known for a while now that most of us eat too much salt and in doing that, it raises blood pressure. But we’re also increasingly recognizing that aldosterone may have a direct impact on causing damage to the blood vessels, to the heart, to the kidneys,” said Dr. Jenifer Brown, one of the lead investigators and co-author of the published study.Brown said she often sees cardiology patients at Brigham and Women’s who may have had a heart event, so she needs to be aggressive in getting their blood pressure under control to prevent another. Some patients may have trouble tolerating other blood pressure medications. For others, the standard medicines just don’t work well. Baxdrostat could be a good complement, she said.“We really have had the same tools as clinicians for many years,” Brown said. “I would be excited to have an option like this.”In an editorial accompanying the publication, Dr. Tomasz Guzik, a cardiovascular scientist at the University of Edinburgh, and Dr. Maciej Tomaszewski, a cardiovascular expert at the University of Manchester, write that next steps should be to figure out which patients would best respond to this new medicine and provide longer-term data. If the medication works long-term, they wrote, it could become a “central piller of therapy for difficult-to-control hypertension.”AstraZeneca said it plans to submit its data to regulatory agencies before the end of 2025.

    Doctors may soon have a new way to treat high blood pressure, even among people for whom medicines haven’t worked well in the past.

    Baxdrostat, an experimental medicine made by AstraZeneca, showed promise in treating people with uncontrolled or resistant high blood pressure in a recent trial. If the medicine gets approved by regulatory authorities, it will be one of the first new approaches to treating high blood pressure in decades, researchers say.

    Scientists presented the trial results Saturday at the European Society of Cardiology Congress 2025 in Madrid and simultaneously published them in the New England Journal of Medicine.

    For the study, researchers enrolled 800 adults who still had high blood pressure after taking two or more medications for at least four weeks. To qualify for the study, patients’ systolic blood pressure had to be between 140 and 170.

    Blood pressure is measured in millimeters of mercury, which is abbreviated as mm Hg. The measurement has an upper number, or systolic reading, and a lower number, a diastolic reading. Systolic pressure measures the force of blood as it pumps out of the heart into the arteries; diastolic is the pressure created as the heart rests between beats.

    Normal blood pressure is less than 120/80 mm Hg, and elevated blood pressure is considered to be from 120 to 129/80 mm Hg. At 130/80 mmHg or higher, according to new U.S. guidelines, a person’s medical provider will want them to take a blood pressure medication if lifestyle changes — including eating healthier, reducing salt in the diet and exercising more — don’t work first.

    The researchers on the new trial placed the participants into three groups. One received 1 milligram of baxdrostat, another got 2 mg, and another got a placebo, which does nothing. Participants took their dose in addition to medicines they were already taking.

    At 12 weeks, about 4 in 10 patients taking baxdrostat reached healthy blood pressure levels, compared with less than 2 in 10 who got a placebo.

    Specifically, participants who got 1 or 2 mg of baxdrostat daily saw their systolic blood pressure – the upper number in the reading – fall around 9 to 10 mm Hg more than those taking a placebo. This reduction, studies show, is large enough to cut cardiovascular risk.

    When blood pressure is high, the force of the blood pushes against the walls of their blood vessels, making the heart less efficient: Both the vessels and the heart must work harder, and it’s more difficult to get blood to essential organs and cells. Without treatment, high blood pressure will eventually damage the arteries, raising the risk of conditions like a heart attack, stroke, coronary disease, vascular dementia and cognitive problems.

    Heart disease is the No. 1 killer in the world. Lowering blood pressure is the most modifiable way to avoid such a death.

    Nearly half of all adults in the U.S. have higher than normal blood pressure, and 1 in 10 people have what doctors call resistant hypertension: Despite being on three or more medications, they are not meeting the goal for blood pressure control.

    When a patient has high blood pressure, doctors may need to try a variety of medications to see what works best.

    Adding baxdrostat to the list of options could be a big help for patients, according to Dr. Stacey E. Rosen, volunteer president of the American Heart Association, who was not involved with the new research.

    “What’s interesting about this medication is that they can really be a wonderful partner, so to speak, with some of the more classically recommended anti-hypertensive medications,” said Rosen, who is also a senior vice president of women’s health and executive director of the Katz Institute for Women’s Health of Northwell Health in New York City.

    Medication options now on the market control blood pressure in a variety of ways. Some, such as vasodilators, relax and widen arteries and veins to allow blood to get through easier and increase flow. Diuretics primarily work by removing excess fluid and salt from the body by increasing urine production. Centrally acting alpha agonists help prevent the nervous system from responding to stress. ACE inhibitors keep the body from producing angiotensin II, a hormone that makes blood vessels constrict. ARBs, or angiotensin II receptor blockers, help reduce the production of aldosterone, a hormone that promotes salt and water retention. Calcium channel blockers can keep calcium away from the cells of the heart and arteries so they don’t have to work as hard.

    Each can have different side effects, including dizziness, rapid or slower heart rate, exhaustion, upset stomach and swelling in the legs.

    Baxdrostat’s side effects, the study showed, were mild overall. The most common problem was abnormalities in potassium and sodium levels, but this was rare.

    Baxdrostat takes a new approach to managing high blood pressure. It focuses on blocking aldosterone, a hormone created by the adrenal glands that helps kidneys regulate salt and maintain the body’s water balance. Some people produce too much aldosterone, leading their body to retain too much water and salt, pushing up blood pressure.

    “We’ve also known for a while now that most of us eat too much salt and in doing that, it raises blood pressure. But we’re also increasingly recognizing that aldosterone may have a direct impact on causing damage to the blood vessels, to the heart, to the kidneys,” said Dr. Jenifer Brown, one of the lead investigators and co-author of the published study.

    Brown said she often sees cardiology patients at Brigham and Women’s who may have had a heart event, so she needs to be aggressive in getting their blood pressure under control to prevent another. Some patients may have trouble tolerating other blood pressure medications. For others, the standard medicines just don’t work well. Baxdrostat could be a good complement, she said.

    “We really have had the same tools as clinicians for many years,” Brown said. “I would be excited to have an option like this.”

    In an editorial accompanying the publication, Dr. Tomasz Guzik, a cardiovascular scientist at the University of Edinburgh, and Dr. Maciej Tomaszewski, a cardiovascular expert at the University of Manchester, write that next steps should be to figure out which patients would best respond to this new medicine and provide longer-term data. If the medication works long-term, they wrote, it could become a “central piller of therapy for difficult-to-control hypertension.”

    AstraZeneca said it plans to submit its data to regulatory agencies before the end of 2025.

    [ad_2]

    Source link

  • No One Can Decide If Grapefruit Is Dangerous

    No One Can Decide If Grapefruit Is Dangerous

    [ad_1]

    Roughly a century ago, a new fad diet began to sweep the United States. Hollywood starlets such as Ethel Barrymore supposedly swore by it; the citrus industry hopped on board. All a figure-conscious girl had to do was eat a lot of grapefruit for a week, or two, or three.

    The Grapefruit Diet, like pretty much all other fad diets, is mostly bunk. If people were losing weight with the regimen, that’s because the citrus was being recommended as part of a portion-controlled, low-calorie, low-carbohydrate diet—not because it had exceptional flab-blasting powers. And yet, the diet has survived through the decades, spawning a revival in the 1970s and ’80s, a dangerous juice-exclusive spin-off called the grapefruit fast, and even a shout-out from Weird Al; its hype still plagues nutritionists today.

    But for every grapefruit evangelist, there is a critic warning of its dangers—probably one with a background in pharmacology. The fruit, for all its tastiness and dietetic appeal, has another, more sinister trait: It raises the level of dozens of FDA-approved medications in the body, and for a select few drugs, the amplification can be potent enough to trigger a life-threatening overdose. For most people, chowing down on grapefruit is completely safe; it would take “a perfect storm” of factors—say, a vulnerable person taking an especially grapefruit-sensitive medication within a certain window of drinking a particular amount of grapefruit juice—for disaster to unfurl, says Emily Heil, an infectious-disease pharmacist at the University of Maryland. But that leaves grapefruit in a bit of a weird position. No one can agree on exactly how much the world should worry about this bittersweet treat whose chemical properties scientists still don’t fully understand.

    Grapefruit’s medication-concentrating powers were discovered only because of a culinary accident. Some three decades ago, the clinical pharmacologist David Bailey (who died earlier this year) was running a trial testing the effects of alcohol consumption on a blood-pressure medication called felodipine. Hoping to mask the distinctive taste of booze for his volunteers, Bailey mixed it with grapefruit juice, and was shocked to discover that blood levels of felodipine were suddenly skyrocketing in everyone—even those in the control group, who were drinking virgin grapefruit juice.

    After running experiments on himself, Bailey confirmed that the juice was to blame. Some chemical in grapefruit was messing with the body’s natural ability to break down felodipine in the hours after it was taken, causing the drug to accumulate in the blood. It’s the rough physiological equivalent of jamming a garbage disposal: Waste that normally gets flushed just builds, and builds, and builds. In this case, the garbage disposal is an enzyme called cytochrome P450 3A4—CYP3A4 for short—capable of breaking down a whole slate of potentially harmful chemicals found in foods and meds. And the jamming culprit is a compound found in the pulp and peel of grapefruit and related citrus, including pomelos and Seville oranges. It doesn’t take much: Even half a grapefruit can be enough to trigger a noticeable interaction, says George Dresser, a pharmacologist at Western University, in Ontario.

    The possible consequences of these molecular clogs can sometimes get intense. “On the list of concerning food-drug interactions,” Dresser told me, “arguably, this is the most important one.” When paired with certain heart medications, grapefruit could potentially cause arrhythmias; with some antidepressants, it might induce nausea, vomiting, and an elevated heart rate. Grapefruit can also raise blood levels of the cholesterol drugs atorvastatin and simvastatin, prompting muscle pain and, eventually, muscle breakdown. One of the fruit’s most worrying interactions occurs with an immunosuppressive drug called tacrolimus, frequently prescribed to organ-transplant patients, that may, when amped up by grapefruit, spark headaches, tremors, hypoglycemia, and kidney problems. The citrus even has the ability to lift blood levels of drugs of abuse, including fentanyl, oxycodone, and ketamine.

    The full list of potential interactions is long. “More than 50 percent of drugs on the market are metabolized by CYP3A4,” which inhabits both the liver and the gut, says Mary Paine, a pharmacologist at Washington State University. That said, grapefruit can really affect only intestinal CYP3A4, and will cause only a small fraction of those medications to reach notably higher concentrations in the blood (and sometimes only when fairly large quantities of juice are consumed—a quart or more). And only a small fraction of those medications will, when amassed, threaten true toxicity. Our bodies are always making more CYP3A4; stop eating grapefruit and, within a day or two, levels of the protein should more or less reset.

    Professionals disagree on how to characterize grapefruit’s risks. To Shirley Tsunoda, a pharmacist at UC San Diego, “it’s definitely a big deal,” especially for the organ-transplant patients to whom she prescribes tacrolimus. Her advice to them is to indulge in grapefruit exactly never—and ideally, tacrolimus-takers should skip related citrus too. Tsunoda even advises people to check the labels of mixed-fruit juices, just in case the makers sneaked some grapefruit in, and she thinks twice when considering noshing on it herself. Paul Watkins, a pharmacologist at the University of North Carolina at Chapel Hill, is much less worried; his bigger concern, he told me, is that the fruit’s reputation as a nemesis of oral medications has been way overblown. He used to study grapefruit-drug interaction but abandoned it years ago, after “I came to the conclusion that it wasn’t very important,” he told me. Some concern is absolutely warranted for certain people on certain meds, he noted. But “I think the actual incidence of patients who have gotten into any kind of trouble or had serious adverse reactions due to taking their drugs with grapefruit juice is very, very small.”

    Even the FDA seems a bit unsure of how it feels about the fruit. The agency has stamped the documentation of several grapefruit-sensitive medications with official warnings. But fact sheets for other drugs merely mention that they can interact with grapefruit, say to consult a health-care professional, or just counsel people to avoid drinking the juice in “large amounts.” And as Dan Nosowitz has reported for Atlas Obscura, several interacting drugs that bear warnings in Canada—among them, Viagra, oxycodone, the HIV antiviral Edurant, and the blood pressure medication verapamildon’t mention any issues with grapefruit in the United States. (When I asked the agency about these discrepancies, a spokesperson wrote, “The FDA is continuously reviewing new information about approved drugs, including studies and reports of adverse events. If the FDA determines there is a safety concern, the agency will take appropriate action.”)

    Very little solid data can precisely quantify grapefruit’s perils. Over the years, researchers have documented a number of isolated cases of citrus-drug interactions that prompted urgent medical care. But some of them involved truly exceptional amounts of juice. And citrus stans aren’t constantly dropping dead in clinical trials or nursing homes. Even when Bailey first presented his findings to the greater medical community, “people asked, ‘Where are all the bodies?’” Dresser, who was mentored by Bailey, told me. The paucity of data, Dresser contends, stems in part from health-care workers neglecting to check their patients for a history of juice-chugging.

    For now, the conversation has mostly stalled, while grapefruit has served up even more mysteries. In the years since Bailey’s discovery, researchers have found that the fruit might lower the concentration of certain drugs, such as the allergy med fexofenadine, perhaps by keeping the lining of the intestines from absorbing certain compounds. New drugs are a particularly murky area, especially because grapefruit interactions aren’t a typical first priority when a new medication hits the market. The popular COVID antiviral pill Paxlovid, for instance, contains the CYP3A4-susceptible ingredient ritonavir. A Pfizer representative told me that the company is not concerned about toxicity. But Heil wonders whether grapefruit could mildly aggravate some of Paxlovid’s irksome side effects: diarrhea, for instance, or maybe the sour, metallic taste that reminds many people of … well, grapefruit.

    That said, most grapefruit lovers need not despair. The fruit is still healthy—chock-full of vitamins and flavor—and yet is often overlooked, says Heidi Silver, a nutrition scientist at Vanderbilt University. Silver and researchers have shown that consuming grapefruit flesh or juice might be able to slightly lower levels of triglycerides and cholesterol. Technically, it can even play a role in weight loss: Snacking on a small portion before a meal can help people feel full faster. Then again, a glass of water will too. Just as grapefruit is not a miraculous vanquisher of fat, it isn’t a ubiquitous killer.

    Even people on certain medications may be able to enjoy it if they consult an expert first. Heil’s own father absolutely adores grapefruit, and also happens to take an oral medication that can interact. Swallow them too close together, and he risks dizziness and fatigue. But he and Heil have found a compromise: He can have small portions of grapefruit or its juice in the morning, spaced about 12 hours out from when he takes his meds at bedtime. A few weeks ago, Heil (who thinks grapefruit is disgusting) even gave her dad the green light to enjoy a dinnertime cocktail that contained a small splash of the juice. Maybe the smidge of fruit affected his meds that day. But “it wasn’t going to be the end of the world,” Heil told me. To say that, after all, would have been an exaggeration.

    [ad_2]

    Katherine J. Wu

    Source link